FPIN's Clinical Inquiries: Are Selective COX-2 Inhibitors as Effective as NSAIDs in Patients with Rheumatoid Arthritis? - February 1, 2004

February 1, 2004 Table of Contents

Clinical Inquiries

FROM THE FAMILY PRACTICE INQUIRIES NETWORK

Are Selective COX-2 Inhibitors as Effective as NSAIDs in Patients with Rheumatoid Arthritis?

Am Fam Physician. 2004 Feb 1;69(3):595-597.

Searchable Question

How effective are selective cyclooxygenase-2 (COX-2) inhibitors in reducing the symptoms of rheumatoid arthritis when compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs)?

Evidence-Based Answer

The efficacy of COX-2 inhibitors is similar to that of nonselective NSAIDs in reducing the symptoms of rheumatoid arthritis. [Strength of Recommendation: A]

Evidence Summary

Four randomized, double-blind, controlled trials1–4 compared the COX-2 inhibitors celecoxib (Celebrex), etoricoxib (Arcoxia), and rofecoxib (Vioxx) with the NSAIDs naproxen (Naprosyn) and diclofenac (Voltaren). Both classes were found to have similar efficacy in nearly all outcomes in patients with rheumatoid arthritis (see the table on the following page). [References 1 through 4—Evidence level 1B]

Only one study1 found significant differences in any outcomes. Patients randomized to the higher celecoxib dosage were more likely to be rated as improved on the patient's and physician's global assessments of disease activity than patients given naproxen (number needed to treat: approximately 10).

A study5 comparing celecoxib with naproxen in the treatment of rheumatoid arthritis or osteoarthritis found similar efficacy between the treatment groups; however, the results were not analyzed separately by arthritis type. [Evidence level 1B]

Recommendations from Others

The London-based National Institute for Clinical Excellence (NICE) recommends the use of COX-2 inhibitors over other NSAIDs only in patients with rheumatoid arthritis who have a high risk of serious gastrointestinal adverse effects.6 NICE recommends against routinely prescribing COX-2 inhibitors in patients with cardiovascular disease (because of a potentially increased risk of myocardial infarction) and patients taking low-dose aspirin (because the gastrointestinal protection of COX-2 inhibitors is reduced).

Clinical Commentary

Physicians can assure their patients with rheumatoid arthritis who are at increased risk of gastrointestinal ulcers that COX-2 inhibitors are as beneficial as nonselective NSAIDs in ameliorating their symptoms. However, there is no clinical reason to routinely prescribe COX-2 inhibitors to patients who do not have an increased risk of ulcers.

Effectiveness of Selective COX-2 Inhibitors and Other NSAIDs in Adult Patients with Rheumatoid Arthritis

Outcome	Trial, number of study participants, dosage comparison
	Collantes, et al., 20024 (n = 445)	Bombardier, et al., 20003 (n = 8,076)	Emery, et al., 19992 (n = 665)	Simon, et al., 19991 (n = 460)	Simon, et al., 19991 (n = 465)
	Etoricoxib (Arcoxia),* 90 mg once daily, versus naproxen (Naprosyn), 500 mg two times daily	Rofecoxib (Vioxx), 50 mg once daily, versus naproxen, 500 mg two times daily	Celecoxib (Celebrex), 200 mg two times daily, versus diclofenac SR (Voltaren SR), 75 mg two times daily	Celecoxib, 200 mg two times daily, versus naproxen, 500 mg two times daily	Celecoxib, 100 mg two times daily, versus naproxen, 500 mg two times daily
Number of tender joints	–	Not assessed	–	–	–
Number of swollen joints	–	Not assessed	–	–	–
Patient's global assessment of pain	–	Not assessed	–	–	–
Functional disability	–	–	–	–	–
Patient's global assessment of disease activity	–	–	–	Better with celecoxib	–
Physician's global assessment of disease activity	–	–	–	Better with celecoxib	–
Percentage of patients meeting ACR-20 criteria†	–	Not assessed	–	–	–
Withdrawals for lack of efficacy	–	–	–	–	–

note:Scales used for outcomes may not be similar between studies. For full details, see the additional table in the online version of this Clinical Inquiry, which is available at http://www.aafp.org/afp/2004/0201/fpin.html.

COX-2 = cyclooxygenase-2 inhibitors; NSAIDs = nonsteroidal anti-inflammatory drugs; — = no significant difference; ACR = American College of Rheumatology.

*—Not approved for use in the United States.

†—ACR-20 is a 20 percent clinical improvement in the tender and swollen joint count and in three of the following factors: patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of pain, degree of disability, and level of acute phase reactant.

Information from references 1 through 4.

JOHN SMUCNY, M.D.

GEORGE CHAI, MS-II

Department of Family Medicine

State University of New York Upstate Medical University

Syracuse, N.Y.

Address correspondence by e-mail to John Smucny, M.D., smucnyj@upstate.edu. Reprints are not available from the authors.

REFERENCES

1. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–8.

2. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106–11.

3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.

4. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10.

5. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96:1019–27.

6. National Institute for Clinical Excellence. Guidance on the use of cyclooxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology appraisal guidance no. 27. London: National Institute for Clinical Excellence, 2001:14. Accessed October 3, 2003, at: http://www.nice.org.uk/pdf/coxiifullguidance.pdf.

Clinical Inquiries provide answers to questions submitted by practicing family physicians to the Family Practice Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/levels_of_evidence.asp).

This series of Clinical Inquiries is coordinated for American Family Physicianby John Epling, M.D., State University of New York Upstate Medical University, Syracuse, N.Y. The complete database of evidence-based questions and answers is copyrighted by FPIN.

Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.